
MP pensions have increased 11.4% over last two years, according to new Treasury Board report
New numbers from the federal Treasury Board indicate that annual MP pensions averaged $81,140 last year.
Article content
That's up 11.4 per cent, compounded over the last two years due to inflation indexing, according to Blacklock's Reporter.
Article content
Article content
The indexation covers retirement allowances, survivor benefits, and disability pensions based on cost-of-living increases.
Article content
Article content
1,193 MPs, retirees and family members are enrolled in the benefits plan. Payments last year included benefits to 192 widows and orphans.
Article content
Article content
To get a pension, MPs must serve for at least six years. Six MPs fell short of that after losing in the recent federal election. That includes ex-Liberals Han Dong (Don Valley North, ON) and Irek Kusmierczyk (Windsor—Tecumseh, ON), and New Democrats Taylor Bachrach (Skeena—Bulkley Valley, BC), Laurel Collins (Victoria), Matthew Green (Hamilton Centre, ON) and Lyndsay Mathyssen (London—Fanshawe, ON).
Article content
Article content
Then in 2005, parliament passed An Act To Amend The Parliament Of Canada Act mandating automatic annual pay hikes for MPs based on inflation and a labour department index of wage settlements in the unionized private sector.
Article content
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Toronto Star
7 minutes ago
- Toronto Star
Tennis star Novak Djokovic among investors to buy a stake in second-tier French soccer club Le Mans
LE MANS, France (AP) — Tennis star Novak Djokovic is part of a group of investors who have bought a stake in French second-tier soccer team Le Mans, along with ex-Formula 1 drivers Felipe Massa and Kevin Magnussen, the club said Friday. Le Mans said in a statement that they join other new financial investors into the club, including Latin American sports investment firm OutField and Georgios Frangulis, the founder and chief executive of OakBerry. Frangulis is the boyfriend of three-time women's Grand Slam champion Aryna Sabalenka.


Winnipeg Free Press
7 minutes ago
- Winnipeg Free Press
Tennis star Novak Djokovic among investors to buy a stake in second-tier French soccer club Le Mans
LE MANS, France (AP) — Tennis star Novak Djokovic is part of a group of investors who have bought a stake in French second-tier soccer team Le Mans, along with ex-Formula 1 drivers Felipe Massa and Kevin Magnussen, the club said Friday. Le Mans said in a statement that they join other new financial investors into the club, including Latin American sports investment firm OutField and Georgios Frangulis, the founder and chief executive of OakBerry. Frangulis is the boyfriend of three-time women's Grand Slam champion Aryna Sabalenka. 'The uniqueness of this fund also lies in its contribution from high-level athletes,' Le Mans president Thierry Gomez said in the statement. 'Novak Djokovic, Felipe Massa, and Kevin Magnussen will be part of the adventure.' No financial details were given. Djokovic is the owner of a men's record 24 Grand Slam titles in tennis. The 38-year-old Serb has won 100 career titles overall. Thursdays Keep up to date on sports with Mike McIntyre's weekly newsletter. Massa won 11 races and secured 41 podiums in his F1 career. When driving for Ferrari, the popular Brazilian was within a whisker of winning the 2008 title, only for Lewis Hamilton to beat him in a dramatic finish at the last race. Hamilton won the title by 98 points to 97. The 32-year-old Magnussen drove close to 200 races in F1, securing one podium and one pole position. But the Danish driver was not retained by Haas at the end of last year when his contract expired. Le Mans soccer club, which is celebrating its 40th anniversary, begins its league campaign on Aug. 9. Le Mans — a small city in northwestern France — also hosts the famed 24-hour endurance car race. ___ AP soccer:


Toronto Star
7 hours ago
- Toronto Star
Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call
MONTREAL, Aug. 01, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) ('Knight'), a pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2025 financial results on Thursday, August 7, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, August 7, 2025 Time: 8:30 a.m. ET Telephone: Toll Free: 1-888-699-1199 or International 1-416-945-7677 Webcast: or Webcast This is a listen-only audio webcast. Media Player is required to listen to the broadcast. Replay: An archived replay will be available for 30 days at ________________________________________ About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or ARTICLE CONTINUES BELOW Forward-Looking Statement This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2024, as filed on Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.